Clinical Correspondence
Prognostic significance of sentinel lymph node status in thin melanoma: a retrospective analysis
Elena S. Meves,
Elena S. Meves
Department of Dermatology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this author Alexander Meves MD,
Corresponding Author
Alexander Meves MD
Department of Dermatology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this author
Elena S. Meves,
Elena S. Meves
Department of Dermatology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this author Alexander Meves MD,
Corresponding Author
Alexander Meves MD
Department of Dermatology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this author
First published: 27 December 2023
No abstract is available for this article.
References
- 1Quattrocchi E, Meves ES, Meves A. CP-GEP (Merlin) gene expression profiling: can my melanoma patient forgo sentinel lymph node biopsy? Ital J Dermatol Venerol. 2023; 158: 292–301.
- 2Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (≤1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Invest Dermatol. 2015; 135: 1190–1193.
- 3Sadurní MB, Meves A. Breslow thickness 2.0: why gene expression profiling is a step toward better patient selection for sentinel lymph node biopsies. Mod Pathol. 2022; 35: 1509–1514.
- 4Bellomo D, Arias-Mejias SM, Ramana C, Heim JB, Quattrocchi E, Sominidi-Damodaran S, et al. Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma. JCO Precis Oncol. 2020; 4: 319–334.
- 5Boland G, Caudle A, Warneke C, Prieto V, Lee JE, Curry J, et al. Predictors of survival in contemporary era patients with thin melanoma who underwent sentinel node biopsy (Abstract 53). Ann Surg Oncol. 2014; 21: S23–S24.
